Home » Pharmaceuticals & Biotech » Acromegaly Pipeline Review and Therapeutics Development H2 2015
“Acromegaly Pipeline Review H2 2015”
Acromegaly – Pipeline Review, H2 2015′, provides an overview of the Acromegaly’s therapeutic pipeline.

New market research titled “Acromegaly – Pipeline Review, H2 2015” to its store. The report provides an overview of the Acromegaly’s therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Inquire more about H2 2015 pipeline review of Acromegaly with 30 market data tables and 15 figures, spread across 87 pages at:
http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=459978

Company Profiles discussed in this report includes Aegis Therapeutics, LLC, Antisense Therapeutics Limited, Chiasma, Inc., Crinetics Pharmaceuticals, Inc., DexTech Medical AB, Foresee Pharmaceuticals, LLC, Ipsen S.A., Isis Pharmaceuticals, Inc., Italfarmaco S.p.A., Novartis AG, Peptron, Inc., Sompharmaceuticals S.A. and Strongbridge Biopharma plc.

Drugs Profiles discussed in this report includes ATL-1103, BIM-23A758, COR-005, FP-002, G-02113, ISIS-GHRLRx, ITF-2984, L-779976, octreotide acetate, octreotide acetate long acting, octreotide acetate SR, octreotide SR, pasireotide ER, Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors, Somadex, SXN-101742 and SXN-101959.

This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.

Complete report is available at:
http://www.rnrmarketresearch.com/acromegaly-pipeline-review-h2-2015-market-report.html

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Acromegaly. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Acromegaly and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects.

A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Acromegaly pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acromegaly
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

More reports on Therapeutics

Media Contact
Company Name: RnRMarketResearch.com
Contact Person: Ritesh Tiwari
Email: sales@rnrmarketresearch.com
Phone: +1 888 391 5441
Address:UNIT No 802, Tower no. 7, SEZ Magarpatta city, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: http://www.rnrmarketresearch.com

Comments are closed.